Welcome to our dedicated page for Transmedics Group SEC filings (Ticker: TMDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TransMedics Group, Inc. (TMDX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. TransMedics is a medical technology company focused on organ transplant therapy, and its filings give detailed insight into how it reports financial performance, manages risks, and documents material events related to its Organ Care System (OCS) and National OCS Program (NOP).
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports to understand revenue from OCS products and NOP services, operating expenses, and discussions of risk factors such as dependence on the OCS platform, regulatory approvals, logistics capabilities, indebtedness, and healthcare policy changes. Form 8-K current reports capture material events, including quarterly financial results, aircraft acquisitions for the NOP fleet, and other significant corporate developments.
TransMedics’ filings also discuss the acquisition and use of fixed-wing aircraft for transporting donor organs, its collaboration and logistics strategy, and the regulatory environment for both its medical devices and aviation transportation services. Disclosures highlight the importance of maintaining FDA and other regulatory approvals for OCS products and licenses for aviation operations.
On Stock Titan, these documents are supplemented with AI-powered summaries that explain key points from lengthy filings, helping users quickly identify information on topics such as revenue drivers, risk factors, and logistics investments. Real-time updates from EDGAR, along with easy access to insider transaction reports on Form 4 and proxy materials on executive and governance matters, make this page a focused resource for analyzing TMDX’s regulatory record and corporate reporting over time.
TransMedics Group, Inc. explains how releasing a U.S. tax valuation allowance changed its previously reported fourth-quarter 2025 results. In Q4 2025 the company released a $103.3 million valuation allowance on deferred tax assets, creating a net income tax benefit of $83.8 million and driving a reported annual effective tax rate of (77.0)%.
For Q4 2025, income before income taxes was $21.6 million. Reported net income was $105.4 million, or $2.62 per diluted share. Using a 19.1% annual effective tax rate excluding the allowance release, adjusted Q4 net income is $17.5 million, or $0.47 per diluted share. The company expects future quarterly tax provisions to align more closely with typical U.S. corporate tax rates.
TransMedics Group, Inc. presents its annual report describing a fast-growing medical technology business built around its Organ Care System (OCS) and National OCS Program (NOP) for heart, lung and liver transplantation.
The company generated $605.5 million of revenue in 2025, up from $441.5 million in 2024 and $241.6 million in 2023, reflecting strong adoption of its single-use disposables and NOP services. TransMedics operates 22 fixed‑wing aircraft, is developing next‑generation and Gen‑3 OCS platforms including OCS Kidney, and is expanding logistics and R&D infrastructure in the U.S. and Europe.
The filing highlights extensive clinical evidence and a large patent portfolio but also notes risks such as fluctuating results, dependence on OCS and NOP, identified material weakness in internal controls, reimbursement dynamics, supply chain reliance, and the need for additional funding and debt service on 1.50% convertible notes due 2028.
TransMedics Group, Inc. reported strong growth for the fourth quarter and full year 2025, driven by broader use of its Organ Care System and related services. Fourth quarter revenue reached $160.8 million, up 32% year over year, while full year 2025 revenue rose to $605.5 million, a 37% increase.
Net income jumped to $105.4 million in the fourth quarter and $190.3 million for the full year, helped by a one-time tax benefit from releasing a valuation allowance on deferred tax assets. The company maintained gross margins around 58–60% and increased investment in research, clinical programs, and commercial infrastructure.
TransMedics completed 5,139 U.S. NOP cases in 2025, expanded its owned aviation fleet to 22 aircraft, and received FDA approval for key heart and lung trials. For 2026, it projects revenue between $727 million and $757 million, implying 20% to 25% growth over 2025.
TransMedics Group, Inc. Chief Commercial Officer Giovanni Cecere reported equity awards consisting of stock options and restricted stock units. He was granted options to purchase 16,734 shares of common stock at an exercise price of $0.00 per share and 11,082 restricted stock units, each representing one share of common stock.
The option award vests as to 25% of the underlying shares on February 18, 2027, with the remaining shares vesting in equal monthly installments over the following three years, subject to continued service. The RSU grant reflects additional direct equity-based compensation tied to the company’s stock.
TransMedics Group, Inc. filed an amended insider ownership report for Chief Commercial Officer Giovanni Cecere. The filing shows he beneficially holds 7,975 restricted stock units (RSUs), each representing a contingent right to receive one share of TransMedics common stock.
These RSUs are reported as directly owned and reflect an equity award rather than an open-market stock purchase or sale. The disclosure updates the market on Cecere’s initial equity-based holdings in the company.
TransMedics Group, Inc. filed an initial ownership report for executive Giovanni Cecere, who serves as Chief Commercial Officer. This Form 3 states that no securities are beneficially owned, meaning Cecere reports holding no TransMedics Group stock or derivative securities as of the event date.
TransMedics Group, Inc. announced leadership transitions in its commercial and legal functions. The Board appointed Giovanni Cecere as Chief Commercial Officer effective February 2, 2026, succeeding Tamer Khayal, M.D., who will become Senior Vice President of International on the same date.
The Board also appointed Matthew Forsyth as Senior Vice President, General Counsel & Corporate Secretary effective March 9, 2026 or his actual start date. Current General Counsel Anil Ranganath will move to a non-executive employee role until June 7, 2026 and then serve as a non-employee consultant until September 7, 2026. His equity awards will continue to vest during his service, and he will receive an annualized consultant fee of $10,000, plus cash severance equal to 0.75 times his highest recent base salary and bonus, COBRA premiums for up to nine months, and a pro-rated 2026 bonus, subject to a release of claims and ongoing covenants.
TransMedics Group, Inc. has signed a long-term lease with BioMed Realty for approximately 498,286 square feet at 188 Assembly Park Drive in Somerville, Massachusetts, which will become its new headquarters and house research, development, lab, manufacturing, assembly, vivarium, office and related functions. The lease term begins on January 8, 2026, with base rent starting on the later of January 1, 2028 or 24 months after term commencement, and running for 192 months from that rent start date.
Initial annual base rent is approximately $23.9 million, increasing 2% each year over the initial term, and the company is expected to bear about 100% of operating and tax expenses for the premises. TransMedics has provided an approximately $18 million letter of credit as a security deposit and holds two 10-year extension options plus a six-month extension option, all subject to customary conditions. Separately, on January 8, 2026, the company acquired two parcels adjacent to the new site in Somerville for $15.0 million each, plus related costs.
TransMedics Group, Inc. (TMDX) reported an insider equity transaction by its Senior Vice President, General Counsel and Secretary. On 11/25/2025, the officer exercised a stock option for 3,000 shares of common stock at an exercise price of $93.88 per share and then sold 3,000 shares of common stock at a weighted average price of $145.22 per share. After these transactions, the officer beneficially owned 13,955 shares of TransMedics common stock directly and held 7,420 stock options directly. The option referenced vested 25% on June 5, 2024 and will continue to vest in equal monthly installments over three years thereafter, subject to continued service.
TransMedics Group, Inc. (TMDX) President & CEO and director Waleed H. Hassanein reported an open-market purchase of company stock. On 11/17/2025, a related revocable trust acquired 8,775 shares of TransMedics common stock at a price of $114 per share. Following this transaction, the trust held 495,009 shares indirectly, while 121,424 shares were held directly in his name. This filing reflects an increase in the insider’s total beneficial ownership of TransMedics shares.